Stock AnalizBiomarin Pharmaceutical Inc. BMRN
Biotechnology: Pharmaceutical Preparations · IPO 1999 · data as of November 13, 2026
Biomarin Pharmaceutical Inc. (BMRN) is a healthcare company listed in the US with a market value of about $11.1B. In the twelve months to September 30, 2026 it had revenue of $3.7B and net income of -$19M, a net margin of -0.5%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (1/5).
Key numbers: a price to free cash flow of 19.9, 5-year revenue growth of 12% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 12% below the current price.
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7B | $3.2B | $2.9B | $2.4B | $2.1B | $1.8B | $1.9B | $1.7B | $1.5B | $1.3B | $1.1B |
| Net income | -$19M | $349M | $427M | $168M | $142M | -$64M | $854M | -$24M | -$77M | -$117M | -$630M |
| Free cash flow | $558M | $725M | $487M | $63M | $55M | $209M | -$29M | -$97M | -$124M | -$208M | -$376M |
| EPS (diluted) | $-0.10 | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| Net margin | -0.5% | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
| ROIC | — | 4.4% | 6.1% | 2.7% | 2.7% | -1.3% | -0.7% | -2.0% | -1.7% | -0.3% | -17.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $90.78, 59% above the current price; targets range from $60.00 to $120.00; the consensus rating is “Buy”; expected EPS is $3.03 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Biomarin Pharmaceutical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 12% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biomarin Pharmaceutical pay a dividend?
Not currently.
Is Biomarin Pharmaceutical a good stock to buy?
We do not give buy or sell advice. Biomarin Pharmaceutical scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.